JP2004534533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534533A5 JP2004534533A5 JP2003500199A JP2003500199A JP2004534533A5 JP 2004534533 A5 JP2004534533 A5 JP 2004534533A5 JP 2003500199 A JP2003500199 A JP 2003500199A JP 2003500199 A JP2003500199 A JP 2003500199A JP 2004534533 A5 JP2004534533 A5 JP 2004534533A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- peptide
- condition
- ntp peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000002775 capsule Substances 0.000 claims 8
- 210000002784 stomach Anatomy 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 6
- 210000000481 breast Anatomy 0.000 claims 5
- 210000002808 connective tissue Anatomy 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 210000001508 eye Anatomy 0.000 claims 5
- 210000000214 mouth Anatomy 0.000 claims 5
- 210000003205 muscle Anatomy 0.000 claims 5
- 210000001331 nose Anatomy 0.000 claims 5
- 210000002741 palatine tonsil Anatomy 0.000 claims 5
- 210000003800 pharynx Anatomy 0.000 claims 5
- 210000002307 prostate Anatomy 0.000 claims 5
- 210000004100 adrenal gland Anatomy 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000000988 bone and bone Anatomy 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 210000001072 colon Anatomy 0.000 claims 4
- 210000003238 esophagus Anatomy 0.000 claims 4
- 210000000232 gallbladder Anatomy 0.000 claims 4
- 210000004392 genitalia Anatomy 0.000 claims 4
- 210000002216 heart Anatomy 0.000 claims 4
- 210000000936 intestine Anatomy 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 210000001165 lymph node Anatomy 0.000 claims 4
- 210000004324 lymphatic system Anatomy 0.000 claims 4
- 210000001672 ovary Anatomy 0.000 claims 4
- 210000000496 pancreas Anatomy 0.000 claims 4
- 230000000849 parathyroid Effects 0.000 claims 4
- 230000001817 pituitary effect Effects 0.000 claims 4
- 210000000664 rectum Anatomy 0.000 claims 4
- 210000003079 salivary gland Anatomy 0.000 claims 4
- 210000003491 skin Anatomy 0.000 claims 4
- 210000000278 spinal cord Anatomy 0.000 claims 4
- 210000000952 spleen Anatomy 0.000 claims 4
- 210000001550 testis Anatomy 0.000 claims 4
- 210000001685 thyroid gland Anatomy 0.000 claims 4
- 210000003932 urinary bladder Anatomy 0.000 claims 4
- 210000004291 uterus Anatomy 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000036244 malformation Effects 0.000 claims 2
- 231100000572 poisoning Toxicity 0.000 claims 2
- 230000000607 poisoning effect Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000027219 Deficiency disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000028782 Hereditary disease Diseases 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- -1 and antibodies Proteins 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 238000000315 cryotherapy Methods 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000005868 electrolysis reaction Methods 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000002647 laser therapy Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29315601P | 2001-05-25 | 2001-05-25 | |
| PCT/CA2002/000759 WO2002097030A2 (en) | 2001-05-25 | 2002-05-24 | Peptides derived from neural thread proteins and their medical use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534533A JP2004534533A (ja) | 2004-11-18 |
| JP2004534533A5 true JP2004534533A5 (enExample) | 2005-12-22 |
| JP4584573B2 JP4584573B2 (ja) | 2010-11-24 |
Family
ID=23127882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003500199A Expired - Fee Related JP4584573B2 (ja) | 2001-05-25 | 2002-05-24 | 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6924266B2 (enExample) |
| EP (1) | EP1390403B1 (enExample) |
| JP (1) | JP4584573B2 (enExample) |
| KR (1) | KR100945383B1 (enExample) |
| CN (1) | CN1582301A (enExample) |
| AT (1) | ATE350396T1 (enExample) |
| AU (1) | AU2002256587B2 (enExample) |
| BR (1) | BR0209990A (enExample) |
| CA (1) | CA2448348C (enExample) |
| CY (1) | CY1111120T1 (enExample) |
| DE (1) | DE60217326T2 (enExample) |
| DK (1) | DK1390403T3 (enExample) |
| ES (1) | ES2278916T3 (enExample) |
| NO (1) | NO334189B1 (enExample) |
| NZ (1) | NZ529911A (enExample) |
| PT (1) | PT1390403E (enExample) |
| WO (1) | WO2002097030A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0207638A (pt) * | 2001-03-08 | 2004-07-27 | Nymox Pharmaceuticals Corp | Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células |
| JP4587667B2 (ja) * | 2001-07-19 | 2010-11-24 | ナイモックス コーポレーション | 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド |
| EP1847550A3 (en) * | 2001-07-19 | 2008-01-09 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| WO2005075647A1 (en) * | 2004-02-06 | 2005-08-18 | Nymox Corporation | Humanized antibody |
| EP1732594A4 (en) * | 2004-03-18 | 2007-10-17 | St Lukes Hospital | METHOD FOR THE ADMINISTRATION OF AGENTS WITH DELAYED RELEASE |
| MX2008011570A (es) * | 2006-03-10 | 2008-09-23 | Nymox Corp | Metodo para prevenir o reducir el riesgo o incidencia de cancer usando peptidos basados en proteina de hebra neural. |
| CN101215323B (zh) * | 2007-12-28 | 2011-11-30 | 首都医科大学宣武医院 | 人ad7c-ntp抗原决定簇多肽、抗体及其在诊断试剂盒上的应用 |
| US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
| US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| US10835538B2 (en) | 2018-03-28 | 2020-11-17 | Nymox Corporation | Method of treating benign prostatic hyperlasia with antibiotics |
| US20200061150A1 (en) | 2018-08-23 | 2020-02-27 | Nymox Corporation | Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function |
| US20200360466A1 (en) | 2019-05-13 | 2020-11-19 | Nymox Corporation | Method of improving lower urinary tract symptoms |
| US11278588B2 (en) | 2019-05-13 | 2022-03-22 | Nymox Corporation | Method of treating lower urinary tract symptoms with fexapotide triflutate |
| US11298400B2 (en) | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
| US11331374B2 (en) | 2019-07-31 | 2022-05-17 | Nymox Corporation | Focal treatment of prostate cancer |
| US11231421B2 (en) | 2019-07-31 | 2022-01-25 | Nymox Corporation | Methods of treating multifocal cancer |
| CN111579799A (zh) * | 2020-06-23 | 2020-08-25 | 江苏省荣军医院 | 一种检测尿液中阿尔茨海默病相关神经丝蛋白的荧光免疫层析试纸的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948634A (en) * | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| DE68927459T2 (de) | 1988-12-21 | 1997-04-24 | Gen Hospital Corp | Nachweis einer neurologischen Krankheit oder einer Funktionsstörung |
| KR20000075748A (ko) * | 1997-02-26 | 2000-12-26 | 마빈 씨. 구트리 | 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계 |
| WO1999019347A1 (en) | 1997-10-10 | 1999-04-22 | Astrazeneca Ab | Synthetic genes with immunomodulatory effects |
| JP2002519311A (ja) * | 1998-06-26 | 2002-07-02 | ジョージタウン・ユニバーシティ・メディカル・センター | 細胞死を誘発するための組成物と方法 |
| US7125957B1 (en) * | 1998-09-30 | 2006-10-24 | Riken | VPR mutant protein and its encoding gene having apoptosis-inducing action |
| WO2000034477A2 (en) * | 1998-12-11 | 2000-06-15 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
| ES2202039T3 (es) * | 1999-01-11 | 2004-04-01 | Leadd B.V. | Uso de agentes inductores de apoptosis en la preparacion de mrdicamentto para el tratamiento de enfermedades autoinmunitarias. |
| JP2002541833A (ja) * | 1999-03-26 | 2002-12-10 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４９個のヒト分泌タンパク質 |
| CA2368927A1 (en) | 1999-03-26 | 2000-10-05 | Craig A. Rosen | 45 human secreted proteins |
| US7259232B1 (en) * | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
| BR0207638A (pt) * | 2001-03-08 | 2004-07-27 | Nymox Pharmaceuticals Corp | Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células |
| DE60205366T2 (de) * | 2001-05-16 | 2006-05-24 | Nymox Corp., Saint-Laurent | Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine |
-
2002
- 2002-05-24 WO PCT/CA2002/000759 patent/WO2002097030A2/en not_active Ceased
- 2002-05-24 JP JP2003500199A patent/JP4584573B2/ja not_active Expired - Fee Related
- 2002-05-24 DK DK02726037T patent/DK1390403T3/da active
- 2002-05-24 BR BR0209990-0A patent/BR0209990A/pt not_active IP Right Cessation
- 2002-05-24 AT AT02726037T patent/ATE350396T1/de active
- 2002-05-24 DE DE60217326T patent/DE60217326T2/de not_active Expired - Lifetime
- 2002-05-24 NZ NZ529911A patent/NZ529911A/en not_active IP Right Cessation
- 2002-05-24 CN CNA028149777A patent/CN1582301A/zh active Pending
- 2002-05-24 AU AU2002256587A patent/AU2002256587B2/en not_active Ceased
- 2002-05-24 US US10/153,334 patent/US6924266B2/en not_active Expired - Fee Related
- 2002-05-24 CA CA2448348A patent/CA2448348C/en not_active Expired - Fee Related
- 2002-05-24 ES ES02726037T patent/ES2278916T3/es not_active Expired - Lifetime
- 2002-05-24 EP EP02726037A patent/EP1390403B1/en not_active Expired - Lifetime
- 2002-05-24 KR KR1020037015376A patent/KR100945383B1/ko not_active Expired - Fee Related
- 2002-05-24 PT PT02726037T patent/PT1390403E/pt unknown
-
2003
- 2003-11-25 NO NO20035231A patent/NO334189B1/no not_active IP Right Cessation
-
2007
- 2007-03-12 CY CY20071100339T patent/CY1111120T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005507647A5 (enExample) | ||
| JP2004534533A5 (enExample) | ||
| JP2005506061A5 (enExample) | ||
| JP2005521383A5 (enExample) | ||
| JP2004529908A5 (enExample) | ||
| JP2019196365A5 (enExample) | ||
| ES2342416T3 (es) | Procedimiento de purificacion o produccion de una proteina mage. | |
| EA010435B1 (ru) | Связывающиеся с tall-1 молекулы и их применение | |
| CN102596217B (zh) | 经修饰的血管活性肠肽 | |
| JP2003531632A (ja) | グルカゴンアンタゴニスト | |
| CA2438143A1 (en) | Modified proteins, designer toxins, and methods of making thereof | |
| JPH06502771A (ja) | 筋細胞内での発現のためのウイルス性組換え型ベクター | |
| KR20090045940A (ko) | 세포자멸사의 억제를 위한 약학 조성물, 및 이를 전달하는 방법 | |
| WO1999048923A1 (en) | Multivalent ligands which modulate angiogenesis | |
| JP2003505075A5 (enExample) | ||
| CN113194978A (zh) | 具有间充质干细胞的动员活性的肽 | |
| JP2003530870A (ja) | Ａｐｏ−ＡＩ／ＡＩＩペプチド誘導体 | |
| CN111690071A (zh) | 一种具有靶向穿膜性的抗肿瘤多肽 | |
| CA2378925A1 (en) | Matrix-targeted fusion polypeptides for tissue regeneration and wound healing | |
| JPH08507205A (ja) | 軟骨礎質の形成を促進する方法 | |
| JP2014516547A (ja) | 骨形成または血管新生促進用ペプチドｂｆｐ４およびその用途 | |
| CN1339973A (zh) | 糖尿病性局部缺血疾病的基因治疗 | |
| JP7457413B2 (ja) | 代謝障害に対する新規なｆｇｆ１９タンパク質類似物質及びその使用 | |
| CN118064445A (zh) | 改进的bFGF编码序列及其修饰细胞的应用 | |
| KR102460983B1 (ko) | 새로운 재생 치료제로서의 camkk1 |